Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Adverse drug reactions

Transplant antifungal drug voriconazole associated with increased skin cancer risk

Researchers have found that voriconazole, used to treat fungal infections after lung transplantation, increases the risk of developing skin cancer by 73%.

Transplant antifungal drug voriconazole associated with increased skin cancer risk

Source: National Institutes of Health. The image is in the public domain.

Voriconazole, an extended-spectrum triazole, is seen as an important agent to treat fungal infections

Antifungal drug voriconazole increases the risk of developing skin cancer by 73% in lung transplant patients given the drug to prevent infection with Aspergillus, according to research published in the American Journal of Transplantation[1] on 3 September 2015.

Patients who undergo a solid organ transplant are at a much higher risk of skin cancer than the general population because of the immune suppressants they have to take. For one of the most common skin cancers, cutaneous squamous cell carcinoma (SCC), the risk is 65 times higher.

Patients are also at high risk of fungal infections, which are a significant cause of disease and death. Voriconazole, an extended-spectrum triazole, has been an “important agent in our armentarium against these infections”, says Haifa Lyster, consultant transplant pharmacist at Royal Brompton & Harefield NHS Foundation Trust in London.

The drug is known to increase the risk of SCC, possibly because it makes the skin more sensitive to light. Now, researchers have defined the benefits and risks more accurately. Overall, any exposure to voriconazole increases the risk of SCC by 73% (hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.04–2.88; P=0.03) — this effect is linked to the cumulative dose. For each additional month of treatment with voriconazole at a dose of 200mg twice a day, the risk of SCC increases by 3% (HR 1.03; 95% CI 1.02–1.04; P<0.001).

The study, led by researchers at the University of California, San Francisco (UCSF), evaluated 455 patients who had a lung transplant at the UCSF hospital between 1991 and 2012.

Lyster says the level of risk could be influenced by sun exposure, which was not monitored in the study. “The lack of relative sun exposure of the patients is an important confounder when assessing risks in less sunnier climates, such as the UK,” she says.

Researchers also assessed whether treatment with voriconazole affected risk of death. For patients without Aspergillus colonisation, there was no impact on the risk of death. But for patients with Aspergillus, the risk of death was reduced by 66% in those who took the drug (HR 0.34; 95% CI 0.13–0.91; P=0.03). “This new research underlines the importance of considering the risk versus benefit for individual patients; one size does not fit all,” says Lyster.

Lung transplant recipients with risk factors for SCC are mainly those who are older, white and male. The authors urge transplant physicians to reconsider the use of high cumulative doses of voriconazole in these patients and in patients lacking evidence of Aspergillus colonisation.

Lyster explains that the hospital in the United States where the study was performed uses prophylaxis with voriconazole more widely than in the UK. “We don’t use voriconazole as primary prophylaxis here,” she points out.

She says that where voriconazole is deemed beneficial, for example when Aspergillus has been identified, it is essential to continue to counsel patients on sun protection, limit the duration of courses and ensure patients are reviewed by a dermatologist as part of their follow-up after transplantation.

“In those patients where a higher risk profile exists, then consideration of an alternative antifungal agent should be considered,” she adds.

Other antifungals, such as amphotericin B and posaconazole, were not associated with an increased risk of SCC, the researchers report.

Lyster notes that the study does have a number of limitations, which the authors acknowledge, such as the lack of smoking history assessment, which is another risk factor for cancer.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069328

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Transplant antifungal drug voriconazole associated with increased skin cancer risk

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.